RenovoRx, Inc. RNXT
0.94 USD -0.11 (-10.29%)
Regular-session close
0.95 +0.01 +1.04%
After hours · Nov 20, 7:07 PM ET
0.9401 Day range 1.05
0.778 52-week range 2.52
- YTD
- +12.14%
- 1 year
- +21.08%
News
globenewswire.com RenovoRx Appoints Interventional Oncology Medtech Leader Richard Stark to its Board of Directors MOUNTAIN VIEW, Calif., Nov. 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company commercializing RenovoCath ® , a patented, FDA-cleared…benzinga.com CORRECTION: RenovoRx Q3 Adj. EPS $(0.07) Misses $(0.06) Estimate, Sales $1.066M Beat $1.065M Estimate RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.06) by 16.67 percent. This is unchanged from the same period last year. The…
benzinga.com RenovoRx Q3 2026 Earnings Call Transcript RenovoRx (NASDAQ:RNXT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com RenovoRx Affirms FY2026 Sales Guidance of $3.750M-$4.250M vs $3.873M Est RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.750 million-$4.250 million to $3.750 million-$4.250 million vs $3.873 million estimate.
benzinga.com RenovoRx Q3 Adj. EPS $(0.08) Misses $(0.06) Estimate, Sales $1.066M Beat $1.065M Estimate RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is unchanged from the same period last year. The…
